The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
A Priori Theoretical Prediction of Selectivity in Asymmetric Catalysis: Design of Chiral Catalysts by Using Quantum Molecular Interaction Fields
作者:James C. Ianni、Venkatachalam Annamalai、Puay-Wah Phuan、Manoranjan Panda、Marisa C. Kozlowski
DOI:10.1002/anie.200600329
日期:2006.8.18
Mousseron; Granger, Bulletin de la Societe Chimique de France, 1947, vol. <5>, p. 850,853
作者:Mousseron、Granger
DOI:——
日期:——
Identification of Amides as Carboxylic Acid Surrogates for Quinolizidinone-Based M<sub>1</sub> Positive Allosteric Modulators
作者:Scott D. Kuduk、Ronald K. Chang、Thomas J. Greshock、William J. Ray、Lei Ma、Marion Wittmann、Matthew A. Seager、Kenneth A. Koeplinger、Charles D. Thompson、George D. Hartman、Mark T. Bilodeau
DOI:10.1021/ml300280g
日期:2012.12.13
Selective activation of the M-1 muscarinic receptor via positive allosteric modulation represents an approach to treat the cognitive decline in patients with Alzheimer's disease. A series of amides were examined as a replacement for the carboxylic acid moiety in a class of quinolizidinone carboxylic acid M-1 muscarinic receptor positive allosteric modulators, and leading pyran 4o and cyclohexane 5c were found to possess good potency and in vivo efficacy.
Winternitz et al., Bulletin de la Societe Chimique de France, 1956, p. 382,387,1827